Targeting apoptosis pathways in childhood malignancies

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 369-373

  Fulda, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Bcl 2; Childhood cancer; IAPs; TRAIL

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; ASPARAGINASE MACROGOL; BH3 PROTEIN; BIM PROTEIN; CASPASE 3; CASPASE 8; DEATH RECEPTOR; ETOPOSIDE; INHIBITOR OF APOPTOSIS PROTEIN; MAPATUMUMAB; NAVITOCLAX; OBLIMERSEN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN BIK; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TOPOTECAN; TRAIL R2 MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; XIAP INHIBITOR;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL (TOPIC); DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; EVENT FREE SURVIVAL; GLIOBLASTOMA; HUMAN; INTRACELLULAR SIGNALING; LEUKEMIA; LYMPHOMA; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SHORT SURVEY; SOLID TUMOR;

INTRACISTERNAL A-PARTICLES;

EID: 84876072692     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.10.003     Document Type: Review

References (50)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Lockshin R.A., Zakeri Z. Cell death in health and disease. J. Cell Mol. Med. 2007, 11:1214-1224.
3. Troeger A., Siepermann M., Escherich G., Meisel R., Willers R., Gudowius S., Moritz T., Laws H.J., Hanenberg H., Goebel U., Janka-Schaub G.E., Mahotka C., Dilloo D. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica 2007, 92:1043-1050.
4. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008, 19:325-331.
5. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 2007, 87:99-163.
6. Okada H., Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 2004, 4:592-603.
7. Fulda S. Tumor resistance to apoptosis. Int. J. Cancer 2009, 124:511-515.
8. Yang X., Thiele C.J. Targeting the tumor necrosis factor-related apoptosis-inducing ligand path in neuroblastoma. Cancer Lett. 2003, 197:137-143.
9. Fulda S., Meyer E., Debatin K.M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002, 21:2283-2294.
10. Petak I., Douglas L., Tillman D.M., Vernes R., Houghton J.A. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin. Cancer Res. 2000, 6:4119-4127.
11. Ehrhardt H., Fulda S., Schmid I., Hiscott J., Debatin K.M., Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003, 22:3842-3852.
12. Van Valen F., Fulda S., Truckenbrod B., Eckervogt V., Sonnemann J., Hillmann A., Rodl R., Hoffmann C., Winkelmann W., Schafer L., Dockhorn-Dworniczak B., Wessel T., Boos J., Debatin K.M., Jurgens H. Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Int. J. Cancer 2000, 88:252-259.
13. Kontny H.U., Hammerle K., Klein R., Shayan P., Mackall C.L., Niemeyer C.M. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis. Cell Death Differ. 2001, 8:506-514.
14. Fulda S. Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy. Anticancer Agents Med. Chem. 2008, 8:533-539.
15. Fakler M., Loeder S., Vogler M., Schneider K., Jeremias I., Debatin K.M., Fulda S. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009, 113:1710-1722.
16. Ashkenazi A., Herbst R.S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest. 2008, 118:1979-1990.
17. Humphreys R.C., Halpern W. Trail receptors: targets for cancer therapy. Adv. Exp. Med. Biol. 2008, 615:127-158.
18. Smith M.A., Morton C.L., Kolb E.A., Gorlick R., Keir S.T., Carol H., Lock R., Kang M.H., Reynolds C.P., Maris J.M., Watkins A.E., Houghton P.J. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr. Blood Cancer 2010, 54:307-310.
19. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9:447-464.
20. Fulda S., Wick W., Weller M., Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 2002, 8:808-815.
21. Dole M., Nunez G., Merchant A.K., Maybaum J., Rode C.K., Bloch C.A., Castle V.P. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res. 1994, 54:3253-3259.
22. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G., Ng S., Nimmer P.M., O'Connor J.M., Oleksijew A., Petros A.M., Reed J.C., Shen W., Tahir S.K., Thompson C.B., Tomaselli K.J., Wang B., Wendt M.D., Zhang H., Fesik S.W., Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
23. Lock R., Carol H., Houghton P.J., Morton C.L., Kolb E.A., Gorlick R., Reynolds C.P., Maris J.M., Keir S.T., Wu J., Smith M.A. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008, 50:1181-1189.
24. Kang M.H., Kang Y.H., Szymanska B., Wilczynska-Kalak U., Sheard M.A., Harned T.M., Lock R.B., Reynolds C.P. Activity of vincristine, l-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007, 110:2057-2066.
25. High L.M., Szymanska B., Wilczynska-Kalak U., Barber N., O'Brien R., Khaw S.L., Vikstrom I.B., Roberts A.W., Lock R.B. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol. Pharmacol. 2010, 77:483-494.
26. Goldsmith K.C., Liu X., Dam V., Morgan B.T., Shabbout M., Cnaan A., Letai A., Korsmeyer S.J., Hogarty M.D. BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma. Oncogene 2006, 25:4525-4533.
27. Lestini B.J., Goldsmith K.C., Fluchel M.N., Liu X., Chen N.L., Goyal B., Pawel B.R., Hogarty M.D. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol. Ther. 2009, 8:1587-1595.
28. Goldsmith K.C., Lestini B.J., Gross M., Ip L., Bhumbla A., Zhang X., Zhao H., Liu X., Hogarty M.D. BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. Cell Death Differ. 2010, 17:872-882.
29. Rheingold S.R., Hogarty M.D., Blaney S.M., Zwiebel J.A., Sauk-Schubert C., Chandula R., Krailo M.D., Adamson P.C. Children's Oncology Group, Phase I Trial of G3139, a Bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. J. Clin. Oncol. 2007, 25:1512-1518.
30. Salvesen G.S., Duckett C.S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 2002, 3:401-410.
31. LaCasse E.C., Mahoney D.J., Cheung H.H., Plenchette S., Baird S., Korneluk R.G. IAP-targeted therapies for cancer. Oncogene 2008, 27:6252-6275.
32. Bertrand M.J., Milutinovic S., Dickson K.M., Ho W.C., Boudreault A., Durkin J., Gillard J.W., Jaquith J.B., Morris S.J., Barker P.A. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 2008, 30:689-700.
33. Festjens N., Vanden Berghe T., Cornelis S., Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ. 2007, 14:400-410.
34. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 2003, 3:46-54.
35. Islam A., Kageyama H., Takada N., Kawamoto T., Takayasu H., Isogai E., Ohira M., Hashizume K., Kobayashi H., Kaneko Y., Nakagawara A. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000, 19:617-623.
36. Adida C., Berrebi D., Peuchmaur M., Reyes-Mugica M., Altieri D.C. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998, 351:882-883.
37. Azuhata T., Scott D., Takamizawa S., Wen J., Davidoff A., Fukuzawa M., Sandler A. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J. Pediatr. Surg. 2001, 36:1785-1791.
38. Ito R., Asami S., Motohashi S., Ootsuka S., Yamaguchi Y., Chin M., Shichino H., Yoshida Y., Nemoto N., Mugishima H., Suzuki T. Significance of survivin mRNA expression in prognosis of neuroblastoma. Biol. Pharm. Bull. 2005, 28:565-568.
39. Miller M.A., Ohashi K., Zhu X., McGrady P., London W.B., Hogarty M., Sandler A.D. Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: a report from the Children's Oncology Group. J. Pediatr. Hematol. Oncol. 2006, 28:412-417.
40. Troger A., Siepermann M., Mahotka C., Wethkamp N., Bulle H., Laws H.J., Escherich G., Janka-Schaub G., Gobel U., Dilloo D. Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia. Klin. Padiatr. 2007, 219:127-133.
41. Giagkousiklidis S., Vogler M., Westhoff M.A., Kasperczyk H., Debatin K.M., Fulda S. Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res. 2005, 65:10502-10513.
42. Vogler M., Giagkousiklidis S., Genze F., Gschwend J.E., Debatin K.M., Fulda S. Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity. Oncogene 2005, 24:7190-7202.
43. LaCasse E.C., Kandimalla E.R., Winocour P., Sullivan T., Agrawal S., Gillard J.W., Durkin J. Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/GEM640. Ann. NY Acad. Sci. 2005, 1058:215-234.
44. LaCasse E.C., Cherton-Horvat G.G., Hewitt K.E., Jerome L.J., Morris S.J., Kandimalla E.R., Yu D., Wang H., Wang W., Zhang R., Agrawal S., Gillard J.W., Durkin J.P. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin. Cancer Res. 2006, 12:5231-5241.
45. Kim S., Kang J., Qiao J., Thomas R.P., Evers B.M., Chung D.H. Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J. Pediatr. Surg. 2004, 39:516-521.
46. Schultze K., Bock B., Eckert A., Oevermann L., Ramacher D., Wiestler O., Roth W. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 2006, 11:1503-1512.
47. Fulda S., Debatin K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 2004, 64:337-346.
48. Shankar S.L., Mani S., O'Guin K.N., Kandimalla E.R., Agrawal S., Shafit-Zagardo B. Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J. Neurochem. 2001, 79:426-436.
49. Coughlin C.M., Fleming M.D., Carroll R.G., Pawel B.R., Hogarty M.D., Shan X., Vance B.A., Cohen J.N., Jairaj S., Lord E.M., Wexler M.H., Danet-Desnoyers G.-a.H., Pinkus J.L., Pinkus G.S., Maris J.M., Grupp S.A., Vonderheide R.H. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J. Clin. Oncol. 2006, 24:5725-5734.
50. Fest S., Huebener N., Bleeke M., Durmus T., Stermann A., Woehler A., Baykan B., Zenclussen A.C., Michalsky E., Jaeger I.S., Preissner R., Hohn O., Weixler S., Gaedicke G., Lode H.N. Survivin minigene DNA vaccination is effective against neuroblastoma. Int. J. Cancer 2009, 125:104-114.